{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Negative+Dose&page=5", "query": { "intervention": "Negative Dose", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 1153, "total_pages": 116, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Negative+Dose&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Negative+Dose&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-19T23:40:05.654Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05818943", "title": "Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "GRIN-related Disorders" ], "interventions": [ { "name": "Radiprodil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GRIN Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Months to 12 Years" }, "enrollment_count": 24, "start_date": "2023-03-07", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2024-11-15", "last_synced_at": "2026-10-19T23:40:05.654Z", "location_count": 2, "location_summary": "Bethesda, Maryland • New York, New York", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05818943" }, { "nct_id": "NCT05159518", "title": "A Study of PRT2527 in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Sarcoma", "Castrate Resistant Prostate Cancer", "Hormone Receptor Positive HER2 Negative Breast Cancer", "Non-small Cell Lung Cancer", "Solid Tumors With Known MYC Amplification" ], "interventions": [ { "name": "PRT2527", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2022-02-14", "completion_date": "2023-12-06", "has_results": false, "last_update_posted_date": "2023-12-11", "last_synced_at": "2026-10-19T23:40:05.654Z", "location_count": 8, "location_summary": "Denver, Colorado • Celebration, Florida • Sarasota, Florida + 4 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Celebration", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05159518" }, { "nct_id": "NCT01184885", "title": "A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lymphoid Malignancies (New or Relapsed)", "Acute Lymphoblastic Leukemia", "Burkitt Lymphoma", "Lymphoblastic Lymphoma", "Mantle Cell Lymphoma", "Adult T-cell Leukemia/Lymphoma" ], "interventions": [ { "name": "Hyper-CVAD", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2010-07", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2025-05-04", "last_synced_at": "2026-10-19T23:40:05.654Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01184885" }, { "nct_id": "NCT01944215", "title": "Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Molecular Imaging" ], "interventions": [ { "name": "Meal", "type": "DIETARY_SUPPLEMENT" }, { "name": "Exercise", "type": "OTHER" }, { "name": "Sestamibi", "type": "RADIATION" }, { "name": "Caffeine Tablet", "type": "DRUG" }, { "name": "External Heating", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER", "RADIATION", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "70 Years", "sex": "FEMALE", "summary": "40 Years to 70 Years · Female only" }, "enrollment_count": 154, "start_date": "2013-09", "completion_date": "2015-04", "has_results": false, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-10-19T23:40:05.654Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01944215" }, { "nct_id": "NCT01111825", "title": "Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2010-04", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2018-09-26", "last_synced_at": "2026-10-19T23:40:05.654Z", "location_count": 4, "location_summary": "Goodyear, Arizona • Los Angeles, California • New York, New York", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01111825" }, { "nct_id": "NCT05608252", "title": "VS-6766+Abema+Fulv in Met HR+/HER- BC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Hormone Receptor-positive Breast Cancer", "Hormone Receptor Positive HER-2 Negative Breast Cancer" ], "interventions": [ { "name": "VS-6766", "type": "DRUG" }, { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adrienne G. Waks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 63, "start_date": "2023-02-23", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-04-30", "last_synced_at": "2026-10-19T23:40:05.654Z", "location_count": 3, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05608252" }, { "nct_id": "NCT00897026", "title": "Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "fluorescence in situ hybridization", "type": "GENETIC" }, { "name": "immunohistochemistry staining method", "type": "OTHER" } ], "intervention_types": [ "DRUG", "GENETIC", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1195, "start_date": "2008-07", "completion_date": "2012-04-27", "has_results": false, "last_update_posted_date": "2021-08-17", "last_synced_at": "2026-10-19T23:40:05.654Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00897026" }, { "nct_id": "NCT02834247", "title": "A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Triple-Negative Breast Neoplasms", "Carcinoma, Non-Small-Cell Lung", "Head and Neck Carcinoma, Squamous Cell", "Advanced Solid Tumors" ], "interventions": [ { "name": "TAK-659", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2016-08-12", "completion_date": "2018-11-30", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-10-19T23:40:05.654Z", "location_count": 9, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02834247" }, { "nct_id": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor" ], "interventions": [ { "name": "BNT326", "type": "DRUG" }, { "name": "Pumitamig", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Paroxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BioNTech SE", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1438, "start_date": "2025-08-12", "completion_date": "2030-03", "has_results": false, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-19T23:40:05.654Z", "location_count": 19, "location_summary": "Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Hartford", "state": "Connecticut" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Sarasota", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07070232" }, { "nct_id": "NCT01757626", "title": "Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Hu3F8 With GM-CSF", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 186, "start_date": "2012-12", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-10-19T23:40:05.654Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01757626" } ] }